Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754033 | 1.00 | ALDH1A1 (0.39) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL1156606 | 0.99 | ALDH1A1 (0.38) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1580390 | 0.93 | TSHR (0.39) | ALDH1A1TSHRPOLBEPHX2PRMT6 | |
| Fumaric Acid SCHEMBL29536757 | 0.92 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| Fumaric Acid SCHEMBL194496 | 0.92 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| Fumaric Acid SCHEMBL194497 | 0.92 | ALDH1A1 (0.37) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1580286 | 0.92 | P2RX7 (0.40) | ALDH1A1CYP1A2CYP3A4CYP2C19CYP2D6 | |
| SCHEMBL1580574 | 0.90 | TSHR (0.40) | ALDH1A1TSHRPOLBEPHX2PRMT6 | |
| SCHEMBL1581054 | 0.89 | CYP17A1 (0.38) | ALDH1A1TSHRPOLBEPHX2PRMT6 | |
| SCHEMBL9989128 | 0.89 | ALDH1A1 (0.43) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-110200903-B | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2022-07-29 | — | — | CN | claimed |
| EP-2866788-B1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-12-16 | — | — | EP | claimed |
| CN-110917130-A | Liquid formulations of amines and organic acids stabilized with salts | 武田药品工业株式会社 | 2020-03-27 | — | — | CN | claimed |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | claimed |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-29 | — | — | US | claimed |
| EP-2309985-B1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | claimed |
| EP-2385983-B1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2017-12-20 | — | — | EP | claimed |
| EP-2564833-B1 | Photostabilized pharmaceutical composition | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-20 | — | — | EP | claimed |
| US-9186411-B2 | Pharmaceutical composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | claimed |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | claimed |
| EP-2309985-A2 | PHARMACEUTICAL COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-1919865-B1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2011-04-06 | — | — | EP | claimed |
| WO-2010013823-A2 | PHARMACEUTICAL COMPOSITION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-04 | — | — | WO | claimed |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2009-11-05 | — | — | US | claimed |
| US-20090143444-A1 | ACID SECRETION INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-04 | — | — | US | claimed |
| US-7498337-B2 | Acid secretion inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-03 | — | — | US | claimed |
| EP-1919865-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-05-14 | — | — | EP | claimed |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-15 | — | — | US | claimed |
| WO-2007026916-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143444-A1 | ACID SECRETION INHIBITOR | HRH2, VIP, CCKBR | ALDH1A1 2004/4885CYP1A2 1488/4885CYP3A4 964/4885 |
| US-20110124687-A1 | PHARMACEUTICAL COMPOSITION | CYP2C19, MLST8, CYP3A43 | ALDH1A1 1146/4885CYP1A2 146/4885CYP3A4 57/4885 |
| US-20090275591-A1 | 1-HETEROCYCLYLSULFONYL, 2-AMINOMETHYL, 5- (HETERO-) ARYL SUBSTITUTED 1-H-PYRROLE DERIVATIVES AS ACID SECRETION INHIBITOR | HRH2, ASNS, GHSR | ALDH1A1 1773/4885CYP1A2 1545/4885CYP3A4 1244/4885 |
| US-20190070159-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | ALDH1A1 3026/4885CYP1A2 2705/4885CYP3A4 516/4885 |
| US-20070060623-A1 | antiulcer agents; proton pump inhibitors; side effect reduction; 1-[4-fluoro-5-phenyl-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine; superior acid secretion inhibitory effect; peptic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, or symptomatic gastroesophageal reflux disease | HRH2, GIPR, HRH4 | ALDH1A1 1043/4885CYP1A2 1624/4885CYP3A4 980/4885 |
| US-20180085361-A1 | NOVEL PHARMACEUTICAL USES | ATP1A4, HRH2, ATP4A | ALDH1A1 3026/4885CYP1A2 2705/4885CYP3A4 516/4885 |
| US-20230143246-A1 | LIQUID PREPARATIONS OF AMINES AND ORGANIC ACIDS STABILIZED BY SALTS | OTC, SLC38A7, SRI | ALDH1A1 795/4885CYP1A2 254/4885CYP3A4 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.